← All trials
NCT04876716
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2021
- Primary completion
- Aug 1, 2026
- Completion date
- Dec 1, 2026
- First posted
- May 6, 2021
- Last posted
- Oct 8, 2021
- Enrollment
- 650
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Erasmus University RotterdamLead sponsor
- Erasmus University RotterdamReponsible party - principal investigator
- Erasmus University RotterdamOverall official - principal investigator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- HOVON - Dutch Haemato-Oncology AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.